39 results
8-K
EX-2.1
CHRS
Coherus Biosciences Inc
22 Jan 24
Coherus Announces Agreement to Divest Ophthalmology Franchise to Sandoz in Conference Call Information
8:01am
a Material Adverse Effect if not otherwise excluded by another clause of this definition), or (ix) any pandemic, public health event, outbreak of disease
8-K
EX-99.1
CHRS
Coherus Biosciences Inc
6 Nov 23
Coherus BioSciences Reports Third Quarter 2023 Financial Results and Business Highlights
4:31pm
; risks relating to the COVID-19 pandemic; risks related to our existing and potential collaboration partners; risks of Coherus’ competitive position
8-K
EX-99.1
CHRS
Coherus Biosciences Inc
27 Oct 23
Regulation FD Disclosure
4:19pm
. Additionally, more than 30 drugs are currently in clinical development. During the COVID-19 pandemic, Junshi Biosciences actively shouldered the social … and uncertainties inherent in the clinical drug development process; risks relating to the COVID-19 pandemic; risks related to our existing
8-K
EX-99.1
3uusd8oi5kyaw9c
2 Aug 23
Coherus BioSciences Reports Second Quarter 2023 Financial Results and Business Highlights
4:05pm
424B3
kb3g1mukm7m5c1pe76v
26 Jul 23
Prospectus supplement
4:59pm
S-4/A
3y5wi
24 Jul 23
Registration of securities issued in business combination transactions (amended)
4:42pm
S-4
3wk21hl
7 Jul 23
Registration of securities issued in business combination transactions
5:03pm
425
iapz7xv
16 Jun 23
Business combination disclosure
8:08am
425
om9ku8n o5
16 Jun 23
Business combination disclosure
7:09am
8-K
EX-2.1
awz up4ysaq
16 Jun 23
Coherus to Acquire Surface Oncology
7:06am
424B5
0evjt9
17 May 23
Prospectus supplement for primary offering
4:02pm
424B5
ym6w3n y3yxqa9hmt
16 May 23
Prospectus supplement for primary offering
6:07am
8-K
EX-99.1
phv88s2j81t1wkdv30
8 May 23
Coherus BioSciences Reports First Quarter 2023 Financial Results and Business Highlights
4:16pm
8-K
EX-99.1
2a69ad
8 Nov 22
Coherus BioSciences Reports Third Quarter 2022 Results and Provides Business Update
4:01pm